Aurobindo Pharma, a major player in the pharmaceutical industry, has announced that it has received approval from the US Food and Drug Administration (USFDA) for its Dextromethorphan Polistirex extended-release oral suspension, dosed at 30 mg/5 mL. This over-the-counter product is designed to offer temporary relief from coughs caused by minor throat and bronchial irritation, particularly those associated with the common cold or inhaled irritants. The formulation is bioequivalent and therapeutically equivalent to the reference listed drug, Delsym, marketed by RB Health (US) LLC. The product will be manufactured at APL Healthcare's Unit IV and is expected to be launched in the second quarter of fiscal year 2027. According to Nielsen data, the estimated market size for this product is around $138 million. Following this approval, Aurobindo Pharma has achieved a total of 580 Abbreviated New Drug Application (ANDA) approvals from the USFDA, which includes 557 final approvals and 23 tentative approvals. The announcement was made on April 17, 2026, after market hours, and Aurobindo Pharma reported a 7.6% increase in consolidated net profit to ₹910.29 crore for the third quarter of fiscal year 2026 compared to the same period last year.